Effects of single Vitamin D 3 injection (200,000 units) on serum fibroblast growth factor 23 and sclerostin levels in subjects with Vitamin D deficiency

Dongdong Zhang, Da Hea Seo, Han Seok Choi, Hye Sun Park, Yoon Sok Chung, Sungkil Lim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Vitamin D deficiency remains common in all age groups and affects skeletal and non-skeletal health. Fibroblast growth factor 23 is a bone-derived hormone that regulates phosphate and 1,25-dihydroxyvitamin D homeostasis as a counter regulatory factor. 1,25-Dihydroxyvitamin D stimulates fibroblast growth factor 23 synthesis in bone, while fibroblast growth factor 23 suppresses 1,25-dihydroxyvitamin D production in the kidney. The aim of this study was to evaluate the effects of vitamin D3 intramuscular injection therapy on serum fibroblast growth factor 23 concentrations, and several other parameters associated with bone metabolism such as sclerostin, dickkopf-1, and parathyroid hormone. Methods: A total of 34 subjects with vitamin D deficiency (defined by serum 25-hydroxyvitamin D levels below 20 ng/mL) were randomly assigned to either the vitamin D injection group (200,000 units) or placebo treatment group. Serum calcium, phosphate, urine calcium/creatinine, serum 25-hydroxyvitamin D, fibroblast growth factor 23, sclerostin, parathyroid hormone, and dickkopf-1 levels were serially measured after treatment. Results: Comparing the vitamin D injection group with the placebo group, no significant changes were observed in serum fibroblast growth factor 23, parathyroid hormone, or dickkopf-1 levels. Serum sclerostin concentrations transiently increased at week 4 in the vitamin D group. However, these elevated levels declined later and there were no statistically significant differences as compared with baseline levels. Conclusion: Serum fibroblast factor 23, sclerostin, parathyroid hormone, and dickkopf-1 levels were not affected significantly by single intramuscular injection of vitamin D3.

Original languageEnglish
Pages (from-to)451-459
Number of pages9
JournalEndocrinology and Metabolism
Volume32
Issue number4
DOIs
Publication statusPublished - 2017 Dec 1

Fingerprint

Vitamin D Deficiency
Cholecalciferol
Injections
Parathyroid Hormone
Serum
Vitamin D
Intramuscular Injections
Bone and Bones
Placebos
fibroblast growth factor 23
Creatinine
Homeostasis
Therapeutics
Age Groups
Fibroblasts
Phosphates
Urine
Hormones
Calcium
Kidney

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

@article{f183225cfc974b43bd229a6641f40e06,
title = "Effects of single Vitamin D 3 injection (200,000 units) on serum fibroblast growth factor 23 and sclerostin levels in subjects with Vitamin D deficiency",
abstract = "Background: Vitamin D deficiency remains common in all age groups and affects skeletal and non-skeletal health. Fibroblast growth factor 23 is a bone-derived hormone that regulates phosphate and 1,25-dihydroxyvitamin D homeostasis as a counter regulatory factor. 1,25-Dihydroxyvitamin D stimulates fibroblast growth factor 23 synthesis in bone, while fibroblast growth factor 23 suppresses 1,25-dihydroxyvitamin D production in the kidney. The aim of this study was to evaluate the effects of vitamin D3 intramuscular injection therapy on serum fibroblast growth factor 23 concentrations, and several other parameters associated with bone metabolism such as sclerostin, dickkopf-1, and parathyroid hormone. Methods: A total of 34 subjects with vitamin D deficiency (defined by serum 25-hydroxyvitamin D levels below 20 ng/mL) were randomly assigned to either the vitamin D injection group (200,000 units) or placebo treatment group. Serum calcium, phosphate, urine calcium/creatinine, serum 25-hydroxyvitamin D, fibroblast growth factor 23, sclerostin, parathyroid hormone, and dickkopf-1 levels were serially measured after treatment. Results: Comparing the vitamin D injection group with the placebo group, no significant changes were observed in serum fibroblast growth factor 23, parathyroid hormone, or dickkopf-1 levels. Serum sclerostin concentrations transiently increased at week 4 in the vitamin D group. However, these elevated levels declined later and there were no statistically significant differences as compared with baseline levels. Conclusion: Serum fibroblast factor 23, sclerostin, parathyroid hormone, and dickkopf-1 levels were not affected significantly by single intramuscular injection of vitamin D3.",
author = "Dongdong Zhang and Seo, {Da Hea} and Choi, {Han Seok} and Park, {Hye Sun} and Chung, {Yoon Sok} and Sungkil Lim",
year = "2017",
month = "12",
day = "1",
doi = "10.3803/EnM.2017.32.4.451",
language = "English",
volume = "32",
pages = "451--459",
journal = "Endocrinology and Metabolism",
issn = "2093-596X",
publisher = "Korean Endocrine Society",
number = "4",

}

Effects of single Vitamin D 3 injection (200,000 units) on serum fibroblast growth factor 23 and sclerostin levels in subjects with Vitamin D deficiency . / Zhang, Dongdong; Seo, Da Hea; Choi, Han Seok; Park, Hye Sun; Chung, Yoon Sok; Lim, Sungkil.

In: Endocrinology and Metabolism, Vol. 32, No. 4, 01.12.2017, p. 451-459.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of single Vitamin D 3 injection (200,000 units) on serum fibroblast growth factor 23 and sclerostin levels in subjects with Vitamin D deficiency

AU - Zhang, Dongdong

AU - Seo, Da Hea

AU - Choi, Han Seok

AU - Park, Hye Sun

AU - Chung, Yoon Sok

AU - Lim, Sungkil

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Background: Vitamin D deficiency remains common in all age groups and affects skeletal and non-skeletal health. Fibroblast growth factor 23 is a bone-derived hormone that regulates phosphate and 1,25-dihydroxyvitamin D homeostasis as a counter regulatory factor. 1,25-Dihydroxyvitamin D stimulates fibroblast growth factor 23 synthesis in bone, while fibroblast growth factor 23 suppresses 1,25-dihydroxyvitamin D production in the kidney. The aim of this study was to evaluate the effects of vitamin D3 intramuscular injection therapy on serum fibroblast growth factor 23 concentrations, and several other parameters associated with bone metabolism such as sclerostin, dickkopf-1, and parathyroid hormone. Methods: A total of 34 subjects with vitamin D deficiency (defined by serum 25-hydroxyvitamin D levels below 20 ng/mL) were randomly assigned to either the vitamin D injection group (200,000 units) or placebo treatment group. Serum calcium, phosphate, urine calcium/creatinine, serum 25-hydroxyvitamin D, fibroblast growth factor 23, sclerostin, parathyroid hormone, and dickkopf-1 levels were serially measured after treatment. Results: Comparing the vitamin D injection group with the placebo group, no significant changes were observed in serum fibroblast growth factor 23, parathyroid hormone, or dickkopf-1 levels. Serum sclerostin concentrations transiently increased at week 4 in the vitamin D group. However, these elevated levels declined later and there were no statistically significant differences as compared with baseline levels. Conclusion: Serum fibroblast factor 23, sclerostin, parathyroid hormone, and dickkopf-1 levels were not affected significantly by single intramuscular injection of vitamin D3.

AB - Background: Vitamin D deficiency remains common in all age groups and affects skeletal and non-skeletal health. Fibroblast growth factor 23 is a bone-derived hormone that regulates phosphate and 1,25-dihydroxyvitamin D homeostasis as a counter regulatory factor. 1,25-Dihydroxyvitamin D stimulates fibroblast growth factor 23 synthesis in bone, while fibroblast growth factor 23 suppresses 1,25-dihydroxyvitamin D production in the kidney. The aim of this study was to evaluate the effects of vitamin D3 intramuscular injection therapy on serum fibroblast growth factor 23 concentrations, and several other parameters associated with bone metabolism such as sclerostin, dickkopf-1, and parathyroid hormone. Methods: A total of 34 subjects with vitamin D deficiency (defined by serum 25-hydroxyvitamin D levels below 20 ng/mL) were randomly assigned to either the vitamin D injection group (200,000 units) or placebo treatment group. Serum calcium, phosphate, urine calcium/creatinine, serum 25-hydroxyvitamin D, fibroblast growth factor 23, sclerostin, parathyroid hormone, and dickkopf-1 levels were serially measured after treatment. Results: Comparing the vitamin D injection group with the placebo group, no significant changes were observed in serum fibroblast growth factor 23, parathyroid hormone, or dickkopf-1 levels. Serum sclerostin concentrations transiently increased at week 4 in the vitamin D group. However, these elevated levels declined later and there were no statistically significant differences as compared with baseline levels. Conclusion: Serum fibroblast factor 23, sclerostin, parathyroid hormone, and dickkopf-1 levels were not affected significantly by single intramuscular injection of vitamin D3.

UR - http://www.scopus.com/inward/record.url?scp=85038874335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038874335&partnerID=8YFLogxK

U2 - 10.3803/EnM.2017.32.4.451

DO - 10.3803/EnM.2017.32.4.451

M3 - Article

VL - 32

SP - 451

EP - 459

JO - Endocrinology and Metabolism

JF - Endocrinology and Metabolism

SN - 2093-596X

IS - 4

ER -